583 related articles for article (PubMed ID: 21830460)
1. Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome--could new oral anticoagulants solve the problem?
Balaban M; Stanrić V; Rincić G; Ledinsky M; Grbac L; Stancić N; Tomasić H
Acta Clin Croat; 2010 Dec; 49(4):469-77. PubMed ID: 21830460
[TBL] [Abstract][Full Text] [Related]
2. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome.
Della Valle P; Crippa L; Garlando AM; Pattarini E; Safa O; Viganò D'Angelo S; D'Angelo A
Haematologica; 1999 Dec; 84(12):1065-74. PubMed ID: 10586206
[TBL] [Abstract][Full Text] [Related]
3. Venous thrombosis in the antiphospholipid syndrome.
Farmer-Boatwright MK; Roubey RA
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):321-5. PubMed ID: 19228605
[TBL] [Abstract][Full Text] [Related]
4. Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic.
Wittkowsky AK; Downing J; Blackburn J; Nutescu E
Thromb Haemost; 2006 Aug; 96(2):137-41. PubMed ID: 16894455
[TBL] [Abstract][Full Text] [Related]
5. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.
Crowther MA; Ginsberg JS; Julian J; Denburg J; Hirsh J; Douketis J; Laskin C; Fortin P; Anderson D; Kearon C; Clarke A; Geerts W; Forgie M; Green D; Costantini L; Yacura W; Wilson S; Gent M; Kovacs MJ
N Engl J Med; 2003 Sep; 349(12):1133-8. PubMed ID: 13679527
[TBL] [Abstract][Full Text] [Related]
6. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
Agnelli G; Prandoni P; Santamaria MG; Bagatella P; Iorio A; Bazzan M; Moia M; Guazzaloca G; Bertoldi A; Tomasi C; Scannapieco G; Ageno W;
N Engl J Med; 2001 Jul; 345(3):165-9. PubMed ID: 11463010
[TBL] [Abstract][Full Text] [Related]
7. Falsely elevated INRs in warfarin-treated patients with the lupus anticoagulant.
Sanfelippo MJ; Sennet J; McMahon EJ
WMJ; 2000 Jun; 99(3):62-4, 43. PubMed ID: 10927985
[TBL] [Abstract][Full Text] [Related]
8. The management of thrombosis in the antiphospholipid-antibody syndrome.
Khamashta MA; Cuadrado MJ; Mujic F; Taub NA; Hunt BJ; Hughes GR
N Engl J Med; 1995 Apr; 332(15):993-7. PubMed ID: 7885428
[TBL] [Abstract][Full Text] [Related]
9. Potential failure of the International Normalized Ratio (INR) System in the monitoring of oral anticoagulation in patients with lupus anticoagulants.
Della Valle P; Crippa L; Safa O; Tomassini L; Pattarini E; Vigano-D'Angelo S; Grazia Sabbadini M; D'Angelo A
Ann Med Interne (Paris); 1996 Sep; 147 Suppl 1():10-4. PubMed ID: 8952752
[TBL] [Abstract][Full Text] [Related]
10. Acute physical exercise is safe in patients with primary antiphospholipid syndrome with exclusive venous thrombosis and under oral anticoagulation with warfarin.
Garcia CB; Seguro LP; Perandini LA; de Sá Pinto AL; Lima FR; Negrão CE; Bonfa E; Borba EF
Rheumatol Int; 2014 Dec; 34(12):1737-41. PubMed ID: 24825252
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulation monitoring part 1: warfarin and parenteral direct thrombin inhibitors.
Spinler SA; Nutescu EA; Smythe MA; Wittkowsky AK
Ann Pharmacother; 2005 Jun; 39(6):1049-55. PubMed ID: 15855245
[TBL] [Abstract][Full Text] [Related]
12. [Use of warfarin and low range INR in the prevention of recurrent venous thrombosis].
Quintero J; Torres E; Diez-Ewald M; Arteaga-Vizcaíno M; Vizcaíno G; León M; Rodríguez Z; Fernández N
Invest Clin; 2011 Sep; 52(3):230-8. PubMed ID: 21950194
[TBL] [Abstract][Full Text] [Related]
13. Warfarin prophylaxis in the antiphospholipid antibody syndrome.
Stern SD
N Engl J Med; 2003 Dec; 349(26):2568-70; author reply 2568-70. PubMed ID: 14699650
[No Abstract] [Full Text] [Related]
14. Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies.
Perry SL; Samsa GP; Ortel TL
Thromb Haemost; 2005 Dec; 94(6):1196-202. PubMed ID: 16411394
[TBL] [Abstract][Full Text] [Related]
15. [The application of thrombin generation tests to warfarin anticoagulation monitoring].
Chen HY; Ding QL; Zhang LW; Xu GQ; Dai J; Wang XF; Xi XD; Wang HL
Zhonghua Xue Ye Xue Za Zhi; 2008 Mar; 29(3):168-70. PubMed ID: 18788615
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
Cohen H; Doré CJ; Clawson S; Hunt BJ; Isenberg D; Khamashta M; Muirhead N;
Lupus; 2015 Sep; 24(10):1087-94. PubMed ID: 25940537
[TBL] [Abstract][Full Text] [Related]
17. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
Kearon C; Gent M; Hirsh J; Weitz J; Kovacs MJ; Anderson DR; Turpie AG; Green D; Ginsberg JS; Wells P; MacKinnon B; Julian JA
N Engl J Med; 1999 Mar; 340(12):901-7. PubMed ID: 10089183
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa.
Bauer KA
J Thromb Haemost; 2011 Jul; 9 Suppl 1():12-9. PubMed ID: 21781237
[TBL] [Abstract][Full Text] [Related]
19. Inaccuracy of point-of-care international normalized ratio in rivaroxaban-treated patients.
Baruch L; Sherman O
Ann Pharmacother; 2013 Sep; 47(9):1210-2. PubMed ID: 24259738
[TBL] [Abstract][Full Text] [Related]
20. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism.
Mavrakanas T; Bounameaux H
Pharmacol Ther; 2011 Apr; 130(1):46-58. PubMed ID: 21185864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
